Though there are plenty of moments that haven't aged at all well in the classic movie musical Grease, its star Olivia Newton-John does not think it's sexist.
Though there are plenty of moments that haven't aged at all well in the classic movie musical Grease, its star Olivia Newton-John does not think it's sexist.
The Bank of Japan is quietly walking back its unpopular negative interest rates policy with a controversial scheme designed to drive mergers among weaker, smaller lenders, a move some insiders see as a risky deviation into industrial reform. As COVID-19 adds pain for regional banks suffering from years of ultra-low interest rates, the BOJ this month unveiled a plan to pay 0.1% interest on deposits held by lenders that cut costs, boost profits or consolidate. The programme means the BOJ will for the first time offer payouts to a specific industry with the aim of driving reform in that sector.
And another thing: People to be thankful for in 2020.
The twins, who were conjoined at the top of their heads, were separated in a historic surgery in 2017.
VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sectors, is pleased to provide an update and overview regarding its expansion into the functional mushroom wellness sector. With interest in functional and medicinal mushrooms climbing sharply, particularly regarding medicinal opportunities, the outlook appears promising for the sector. Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically. As a study candidate psilocybin is being looked at for treatment options including depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction. The U.S. Food and Drug Administration (USFDA) status on the use of psychedelics appears to be evolving, subsequent to breakthrough therapy status for treatment-resistant depression in 2020 which appears poised to receive approvals in 2021. Recent reports also indicate that the global market for functional mushrooms, is forecasted to reach $34.3 billion USD by 2024 and continues growing at a respectable CAGR of 8%.As a result of the encouraging and growing interest in the sector, Pure Extracts has commenced the expansion of its business model to include mushroom formulations through the use of extraction processes that have proven compatible with its existing infrastructure. The Company is working closely with its scientific advisor, Dr. Alexander MacGregor, the founder of the Toronto Institute of Pharmaceutical Technology, to develop high bio-available products and novel delivery methodologies including pills, capsules, and edibles. Furthermore, the Company believes that there exists a significant opportunity for it to become an important extraction partner for the commercialization of new functional mushroom products designed with purity and consistency in mind. In that regard, Pure Extracts has signed a Letter of Intent (LOI) with one of Canada’s leading functional mushroom wellness brands to co-develop CBD enhanced mushroom products.Looking further ahead, Pure Extracts aims to eventually enter the growing field of psychedelic mushroom processing as an additional aspect of its diverse extraction market penetration strategy. In the interim, three functional products such as lion’s mane, turkey tail and reishi are being created under the ‘Pure Mushrooms’ brand. In herbal medicine, these products are thought to boost memory, support the immune system or reduce stress. Pure Mushrooms products are projected for availability by the end of Q1 2021 via direct-to-consumer sales utilizing the Company’s capital efficient, e-Commerce web portal. The creation of these products will validate the Company’s processes and capabilities and prepare it as additional strains become available.Company CEO, Ben Nikolaevsky notes, “Our brand is an aspirational extension of our location in the mountains of British Columbia. As such, we are 100% focused on high quality ingredients, formulations, and processes in all our efforts. Moving into the field of mushroom extractions is an obvious and exciting opportunity to leverage our advanced technology and proven capabilities. We look forward to launching our functional products commercially within the next few months and can’t help but see the similarities to the cannabis sector regarding the pathways to both medical and recreational legalization. I believe our ability to immediately begin working in this burgeoning sector will create immense value for our business, our stakeholders, partners and shareholders alike.”About Pure Extracts (CSE: PULL) (XFRA: A2QJAJ) The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.For further information please contact Empire Communications Group at (604) 343-2724.ON BEHALF OF THE BOARD “Ben Nikolaevsky” Ben Nikolaevsky CEO and DirectorThe CSE has neither approved nor disapproved the contents of this press release.This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.
"Hello, Liza. This is John Mellencamp. What do you want to talk about?" It’s a cold, cloudy East Coast afternoon, and, for so many reasons, including John’s 69th birthday on Oct. 7, it’s been tough for us to connect. "I want to talk about you," I say. "Boy, that's…
Michael Hancock urged residents to stay at home, before admitting he travelled to Mississippi.
Six members of the Pakistan cricket squad in New Zealand have tested positive for COVID-19 and have been moved from managed isolation into quarantine. Two of the cases are deemed historical and four are new but all six players will move to the quarantine arm of their isolation facility. The Pakistan team’s exemption to train while in managed isolation will be withheld until an investigation has been completed.
Concerns over the accessibility of testing or the ability of testing to produce valid results resulted in the decision to push the exams to 2022.
SPIN launched in the peak MTV era, when an innovative — or even just salacious — music video could make or break an artist. Thirty five years later, YouTube is an obligatory part of any promotional push, but no one’s counting on a mind-blowing clip to sell a record. (The views…
Sink into a brand new mattress and save up to 30 percent — then top it off with buttery soft sheets, cozy blankets, luxurious pillows and more for a steal.
Is Starbucks open on Thanksgiving? Yes, select locations are open Thursday. Select Burger King, McDonald's, Del Taco, also are open this Turkey Day.
What grocery stores are open on Thanksgiving 2020? Albertsons, Kroger and Whole Foods are open, but Aldi, Costco, Walmart and Publix are closed.
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey, and docketed under 20-cv-015228, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Celsion securities between November 2, 2015 and July 10, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are a shareholder who purchased Celsion securities during the class period, you have until December 28, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action]Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment.The OPTIMA Study was expected to enroll 550 patients globally, with up to 100 sites in the U.S., Europe, China and Asia Pacific, to evaluate ThermoDox in combination with RFA. The primary endpoint for the trial was OS, and the statistical plan called for two interim efficacy analyses by an independent Data Monitoring Committee (“DMC”).The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether Boston Scientific and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On November 17, 2020, Boston Scientific announced a global recall of all unused inventory of the Company’s LOTUS Edge Aortic Valve System, citing “complexities associated with the product delivery system.” Boston Scientific further announced that “[g]iven the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately.” On this news, Boston Scientific’s stock price fell $3.00 per share, or 7.89%, to close at $35.03 per share on November 17, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HP Inc. (“HP” or the “Company”) (NYSE: HPQ). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether HP and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On June 21, 2016, HP announced an overhaul to its Printing sales model and revealed that it would reduce the Supplies channel inventory by $450 million in Supplies revenue over the remainder of 2016. On this news, HP’s stock price fell $0.72 per share, or 5.4%, to close at $12.61 per share on June 22, 2016. More than four years later, on September 30, 2020, the U.S. Securities and Exchange Commission (“SEC”) issued a press release, announcing charges against HP “for misleading investors by failing to disclose the impact of sales practices undertaken to meet quarterly sales and earnings targets.” Specifically, the SEC stated that “from early 2015 through the middle of 2016, in an effort to meet quarterly sales targets, regional managers at HP used a variety of incentives to accelerate, or ‘pull-in’ to the current quarter, sales of printing supplies that they otherwise expected to materialize in later quarters.” The press release further stated that “HP has agreed to pay $6 million to settle the charges.” The SEC’s charges against HP revealed that while the Company’s June 21, 2016 announcement had attributed its channel inventory issues and revenue and margin reductions to unfavorable currency impacts, competitive pricing pressure, and a change in inventory modeling, HP had in reality engaged in improper channel inventory management and sales practices.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
As part of our 35th anniversary, we’re naming the most influential artists of the past 35 years. Today, we’re at 11. From Los Angeles, California, here are the Guns N' Roses. Bursting out of the Sunset Strip faster than you can say "Welcome to the Jungle," Guns N’ Roses became both…
Detroit Lions running back Adrian Peterson is ban
China Biologic announced its third quarter 2020 financial results on November 24th, 2020, after the market closed. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.
TRAXX Africa locomotive Since 2007, ongoing production and delivery of our highly reliable locomotives in South Africa marks Bombardier’s commitment to the country’s impressive rail modernization plan. TRAXX locomotive for South Africa Bombardier’s TRAXX Africa locomotive fleet in South Africa completes ten million kilometres in service. * The TRAXX Africa locomotives have each made around 1,600 round trips of 2,200 km and moved over ten million tons of freight since starting service in December 2017 * Ongoing production and delivery of highly reliable locomotives in South Africa marks Bombardier’s commitment to the country’s impressive rail modernization planBERLIN, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Note to editors: To view the photos associated with this press release, please visit the following links: https://www.globenewswire.com/NewsRoom/AttachmentNg/817ad76a-53a4-42b0-b266-0a0afa164ff1 https://www.globenewswire.com/NewsRoom/AttachmentNg/492130a4-71d4-4487-a125-459c8fb42a98Global mobility technology leader Bombardier Transportation announced today that its Transnet locomotive fleet in South Africa has successfully completed ten million kilometres in service since operations began in December 2017. Transnet Freight Rail (TFR) awarded Bombardier the contract to supply 240 electric locomotives in March 2014. Since then, Bombardier has been delivering the BOMBARDIER TRAXX Africa locomotives to Transnet as part of South Africa’s rail modernization plan. In addition, the localized manufacturing is contributing towards skills development in the country and Broad-Based Black Economic Empowerment (B-BBEE) programs.“This achievement is thanks to the close partnerships between Bombardier, Transnet Freight Rail, Transnet Engineering and more than 200 local suppliers who are supporting us in the delivery of these modern electric locomotives,” said Makgola Makololo, Managing Director South Africa at Bombardier Transportation. She added, “We are proud to see our locomotives forming the backbone of the regional freight movement in South Africa and Bombardier is fully committed to this country through our local manufacturing capability, strong local supply chain and job creation that comes with each TRAXX Africa locomotive manufactured here.”The locomotives are being used to transport freight on South Africa’s long routes between its mines and ports. Bombardier has maximized local manufacturing and has assembled the new freight locomotives from the very first unit in South Africa. With more than 60 per cent of the total contract value on local content achieved and around 300 direct and 1,800 indirect local jobs created, we are a well-established local manufacturer and employer that is fully integrated into South Africa’s fabric.Surpassing Contractual Requirements With over ten million tons of freight movement making 1,600 trips of 2,200 km from Hotazel to Port Elizabeth operating with multiple locomotives during each trip, Bombardier is significantly maintaining high fleet availability and reliability for Transnet’s operations. The TRAXX Africa locomotives have been operating at an availability rate of 98 per cent compared to 95 per cent contractual requirement and one failure per million km compared to the target of 15 based on the contract requirements. Bombardier is a B-BBEE level 2 certified company, also exceeding the requirement to maintain B-BBEE level 4 under the contract contributing significantly towards local development programmes for the South African government.About Bombardier Transportation in South Africa With around 300 employees, Bombardier Transportation in South Africa operates a locomotive assembly site in Durban and a propulsion system manufacturing facility in Johannesburg. Bombardier has maintenance depots across South Africa supporting various rail operators and it is a long-standing partner of Gautrain as the supplier of its commuter trains and signalling systems, and it has the contract to maintain the Gautrain fleet until 2026. Bombardier has been a significant contributor to job creation and economic growth in South Africa since 1985.About Bombardier Transportation Bombardier Transportation is a global mobility solution provider leading the way with the rail industry’s broadest portfolio. It covers the full spectrum of solutions, ranging from trains to sub-systems and signalling to complete turnkey transport systems, e-mobility technology and data-driven maintenance services. Combining technology and performance with empathy, Bombardier Transportation continuously breaks new ground in sustainable mobility by providing integrated solutions that create substantial benefits for operators, passengers and the environment. Headquartered in Berlin, Germany, Bombardier Transportation employs around 36,000 people and its products and services operate in over 60 countries.About Bombardier With over 52,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion US. News and information are available at bombardier.com or follow us on Twitter @Bombardier.Notes to Editors For news, related material and photos, visit our newsroom at http://www.rail.bombardier.com/en/newsroom.html. Please subscribe to our RSS Feed to receive press releases or follow Bombardier Transportation on Twitter @BombardierRail.Bombardier and TRAXX are trademarks of Bombardier Inc. or its subsidiaries.For informationMedia relations, South Africa Harsh Mehta +91 98208 02228 email@example.com Global media relations firstname.lastname@example.org You can also contact one of our worldwide contacts for specific press inquiries.
JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that it will hold its 2020 annual general meeting on Tuesday, December 29, 2020 at 10:00 a.m. (Beijing time) at 9F, Jinko Building, 99 Shouyang Road, Jingan District, Shanghai, China, for the following purposes: